Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $5.66 | Change: $-0.12 | %Change: -2.08%
Volume: 10,200 | Day High/Low: 5.83/5.65 | 52 Week High/Low: 10.36/2.55
View modes: 
5 stars


EOM  rate and reply
0 stars

RE:RE:June Is Coming

Ah so Ty for shopping Nuvo come back again soon ūüėÄ  rate and reply
0 stars

RE:June Is Coming

I'd like an update now...0 trades today?  rate and reply
0 stars

June Is Coming

Its news month, starting next week. Updates are always useful.  rate and reply
0 stars

RE:RE:Vally was a good ole Girl

Easy, they got paid off some way...some how to convince the BOD other way to explain it. Most likely they were given shares of Horizon guess.  rate and reply
0 stars

RE:Vally was a good ole Girl

I see what you mean. Those little details that most dont bother to read. In addition, why would they change their rate just for Horizon.  rate and reply
0 stars

RE:Double witching Time

Green!! :))  rate and reply
0 stars

Double witching Time

Weekend and month end for funds to tidy up their books. And, may be a small short thrown in. Whatever. Get your stinker bids in and make good money next week when June and its news arrives..  rate and reply
2 stars

another sucker rally

back to $ 4.50 in two weeks. Keep dreaming.  rate and reply
0 stars

Vally was a good ole Girl

The deal signed with Mally for P2 in 2009 was a very good deal, relative to the times and Mally's obligation to take P2 through its Phase 3 trials. Nuvo got $10 million up front and more
0 stars

RE:RE:Royalty deals outside of the US

Thx, Rocky.  At least Nuvo is able to sign royalty deals.  That Horizon deal was a bit of a head scratcher, unless mgmt had no idea that P2% was so much better than Voltaren.  You'd think they more
0 stars


agreed . Our management and BOD are not known for caring for retail shareholders interest. Their past actions are well known for rewarding themselves richly. That's why SP is low compared to more
0 stars


The battle ahead is quite likely about the appropriate acquisition price. The stock price has been held down and kept down for several months now... the $6 "barrier" today and yesterday a more
3 stars

RE:Royalty deals outside of the US

The Paladin deal for P2 for Canada was done in 2006. It was $500,000 upfront and a 20% royalty on net sales. It must be obvious to everyone by now that Nuvo is probably in play. Not more
3 stars

Product margins higher this year

Mallingcroft began selling P2 in the second quarter of 2014. It was the largest quarter for product sales, as those  petered out once Nuvo began to sue them. Margins on $2.2 million sales in Q2/ more
0 stars

Royalty deals outside of the US

I see from Paladin's website that they have identified P2% as either being in or having completed Phase 3 clinical studies. (I can't tell which from the presentation.) Also, from NRI's MD&A, it more
1 star

RE:Seeking Alpha Article May 26th 2015

This is just a superficial analyses, without reference points to actual P2 sales. It is also only a valuation of P2 product sales to Horizon. Furthermore, the $7 target is in USD ( thats more
1 star

RE:Comment and a question

P2 in Europe will be sold OTC. Its efficacy will not be the main trial. That is evident from the US Phase 3. The main approval criteria will be safety, much like when Voltaren gel got more
3 stars

RE:RE:RE:RE:Profits from P2 sales

Fopr comparison, Cipher will do about $12 million in net profits this year and its market cap is $320 million. The reason ? Nuvo has yet to be promoted in any real way by  professional more
1 star

Seeking Alpha Article May 26th 2015  rate and reply